Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Study of delayed or salvage ASCT -> mPFS 17.5 and mOS 47.3 mos with no significant difference between delayed and salvage ASCT (mPFS 16.3 vs 19.1 mos; mOS 43.2 vs 50.8); salvage ASCT ≥24 mos after 1st assoc with superior outcomes.”
Title: Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma
Authors: Oren Pasvolsky, Curtis Marcoux, Denái R. Milton, Asad A. Haider, Mark R. Tanner, Qaiser Bashir, Samer Srour, Neeraj Saini, Portia Smallbone, Paul Lin, Jeremy Ramdial, Yago Nieto, Ali H. Mohamedi, Umer R. Siddiqui, Abdullah Jamil, Guilin Tang, Yosra Aljawai, Hans C. Lee, Krina K. Patel, Partow Kebriaei, Sheeba K. Thomas, Robert Z. Orlowski, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash
You can read the Full Article in Bone Marrow Transplantation.
You can find more posts featuring Robert Orlowski on OncoDaily.
